LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27 2022 - 10:05AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company
focused on developing its proprietary Gammabody™ platform of
bispecific gamma delta T cell engagers to transform the treatment
of cancer, today announced the Company will present updated interim
data from the dose escalation phase of the ongoing Phase 1/2a
clinical trial of LAVA-051 in patients with relapsed or refractory
chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the
2022 American Society of Clinical Oncology (ASCO) Annual Meeting
taking place in Chicago and virtually June 3-7, 2022.
The details of the poster presentation session are as
follows:
Abstract #: 2577Abstract
Title: Phase I dose escalation of LAVA-051, a novel
bispecific gamma delta T-cell engager (Gammabody™), in
relapsed/refractory hematological malignanciesSession
Title: Developmental Therapeutics —
ImmunotherapySession Date: Sunday, June 5,
2022Session Time: 8–11 a.m. CDT/9 a.m.–12 p.m.
EDTPresenter: Benjamin Winograd, M.D., Ph.D.,
chief medical officer, LAVA Therapeutics
About LAVA TherapeuticsLAVA Therapeutics N.V.
is an immuno-oncology company utilizing its proprietary Gammabody™
platform to develop a portfolio of bispecific gamma delta T cell
engagers for the potential treatment of solid and hematological
malignancies. The Company utilizes bispecific antibodies engineered
to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9
Vdelta2) T cell antitumor effector functions upon cross-linking to
tumor associated antigens. LAVA-051, the Company’s lead candidate
for the treatment of multiple myeloma, chronic lymphocytic leukemia
and acute myeloid leukemia, is enrolling patients in a Phase 1/2a
clinical study (NCT04887259). A Phase 1/2a clinical study to
evaluate LAVA-1207 in patients with metastatic castration-resistant
prostate cancer (mCRPC) is also enrolling. For more information,
please visit www.lavatherapeutics.com, and follow us on LinkedIn,
Twitter and YouTube.
LAVA’s Cautionary
Note on
Forward-Looking StatementsThis
press release contains forward-looking statements, including in
respect to the company’s anticipated growth and clinical
developments plans, including the timing of clinical trials. Words
such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,”
“should,” “plan,” “intend,” “estimate,” “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on LAVA’s expectations and
assumptions as of the date of this press release and are subject to
various risks and uncertainties that may cause actual results to
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the preclinical data,
clinical development and scope of clinical trials, and the
potential use of our product candidates to treat various tumor
targets. Many factors, risks and uncertainties may cause
differences between current expectations and actual results
including, among other things, the timing and results of our
research and development programs and preclinical and clinical
trials, our ability to obtain regulatory approval for and
commercialize our product candidates, our ability to leverage our
initial programs to develop additional product candidates using our
Gammabody™ platform, and the failure of LAVA’s collaborators
to support or advance collaborations or our product candidates. In
addition, the COVID-19 pandemic may disrupt our business and that
of the third parties on which we depend, including delaying or
otherwise disrupting our clinical trials and preclinical studies,
manufacturing and supply chain, or impairing employee productivity.
LAVA assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
CONTACTSEdward SmithChief Financial
Officerir@lavatherapeutics.com
Argot Partners (IR/Media)212-600-1902lava@argotpartners.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024